<span item_type="fundamental" item_id="0782f640e7ac26d812afd352998a1655" counter_id="ST/US/ICUCW" env="prod"></span><span item_type="announcement" item_id="582446339147039105" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 183 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.13.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.686 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenue for the nine months ended September 30, 2025, was $814,000, compared to $68,000 for the same period in 2024, reflecting the commencement of commercial sales of QUELIMMUNE in July 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Loss from operations for the nine months ended September 30, 2025, was $9,159,000, compared to $13,075,000 for the same period in 2024, indicating a reduction in operating losses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li><li>Total operating expenses for the nine months ended September 30, 2025, were $9,932,000, compared to $13,143,000 for the same period in 2024, driven by reductions in research and development and general administrative expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025, was $9,505,000, compared to $11,314,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li><li>Net cash provided by financing activities for the nine months ended September 30, 2025, was $21,449,000, compared to $13,220,000 for the same period in 2024, primarily from equity offerings and warrant exercises.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has nine customer sites for QUELIMMUNE as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue the development of its adult SCD and expand the commercialization of QUELIMMUNE, with a focus on generating significant revenue from product sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring the application of its SCD therapy across a broad range of indications where proinflammatory activated neutrophils and monocytes contribute to disease progression or severity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li><li><strong>Priority</strong>: The company is focused on obtaining additional capital to fund its operations, including clinical trial expenses and capital expenditure requirements, as current cash reserves are insufficient for the next 12 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000143774925034884/icu20250930_10q.htm"></span></li></ul>

SEASTAR MEDICAL HOLDING CORP C/WTS 28/10/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 183 K